Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31691476 | 0.86 | RXFP1 (0.35) | TRPV1FLT3IRAK4ALDH1A1LMNA | |
| SCHEMBL31691304 | 0.86 | KAT7 (0.38) | — | |
| SCHEMBL31691361 | 0.81 | KAT7 (0.36) | — | |
| SCHEMBL31691325 | 0.81 | KAT7 (0.34) | — | |
| SCHEMBL31691277 | 0.80 | KAT7 (0.38) | TRPV1 | |
| SCHEMBL31691260 | 0.78 | KAT7 (0.37) | — | |
| SCHEMBL31691372 | 0.76 | HTT (0.39) | ALDH1A1 | |
| SCHEMBL31691405 | 0.75 | KAT7 (0.39) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31691424 | 0.72 | KLKB1 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL31691398 | 0.71 | KAT7 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304535-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-02 | — | — | US | disclosed |
| WO-2025201504-A1 | KAT6 INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304535-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT2A | TRPV1 4211/4885FLT3 4615/4885IRAK4 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.